New & Noteworthy

November 2018

Butalbital Acetaminophen Capsule

Mayne Pharma (USA) Inc

Butalbital Acetaminophen Capsule

Mayne Pharma Group announces the launch of the butalbital acetaminophen (APAP) capsule 50 mg/300 mg in the United States. This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache (migraine). Complementary to Mayne Pharma’s butalbital/APAP tablet 50 mg/300 mg, this capsule formulation provides alternative treatment choices for patients who previously only had a tablet option. The company expects several product launches within the coming year, with 14 drug applications pending US FDA approval.

Mayne Pharma (USA) Inc

Request More Information

Current Issue